Going off of one of the points Ram asked about the mechanism of ezetimibe:
If a group of patients in the IMPROVE-IT trial or in your clinical practice were identified as carriers of an inactivating NPC1L1 mutation, do you the think the addition of ezetimbe to statin therapy would show the same outcomes as patients without this mutation?
Myocardial Infarction Genetics Consortium I, Stitziel NO, Won HH, et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 2014;371:2072-82.